Introduction
============

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a distinct B-cell lymphoma that develops in extranodal sites and usually has an indolent clinical course as a localized disease ([@B1]). Histologically, MALT lymphoma is classified as a low-grade lymphoma. The tumor cells are small in size, grow in extranodal lymphoid tissue, and infiltrate epithelial tissues, forming lymphoepithelial lesions. It is often difficult to distinguish MALT lymphoma from benign inflammatory conditions. Accumulating clinicopathological studies suggest that the development of MALT lymphoma is often associated with chronic inflammation caused by infections or autoimmune diseases ([@B2]). The latter link has been reported in MALT lymphoma associated with Sjögren\'s syndrome in the salivary gland and with Hashimoto\'s disease in the thyroid. The best known example of the former link is the association between gastric MALT lymphoma and chronic gastritis caused by *Helicobacter pylori* ([@B3]). The growth and maintenance of gastric MALT lymphoma may be dependent on stimulation by *H. pylori* antigen; malignant lymphoid cells may respond specifically to *H. pylori* antigen ([@B4]), and the lymphoma is known to regress with eradication of the infectious agent ([@B5]). Interestingly, gastric MALT lymphomas possessing the *API2-MALT1* fusion, a MALT-lymphoma-specific gene alteration, show resistance to *H. pylori* eradication therapy ([@B6]). Other suspected links include those of *B. burgdorferi* in cutaneous MALT lymphoma, hepatitis C virus in hepatic MALT lymphoma, and *C. psittaci* in ocular adnexal MALT lymphoma ([@B7]-[@B9]).

Recently, a European research group examined pulmonary MALT lymphoma cases and reported that approximately half were positive for *Achromobacter xylosoxidans* (*A. xylosoxidans*) DNA, suggesting that *A. xylosoxidans* has an etiological role in the development of pulmonary MALT lymphoma ([@B10]). *A. xylosoxidans* is a Gram-negative, aerobic, and oxidase-positive bacillus ([@B11]). It is an opportunistic pathogen that can cause a wide variety of infections in immunocompromised patients ([@B12]-[@B15]) but is mainly recovered from the airways of cystic fibrosis patients ([@B16]). The association between pulmonary MALT lymphoma and *A. xylosoxidans* has attracted a considerable attention. However, the association showed potential geographical variability and needs to be confirmed by independent series across different countries ([@B17],[@B18]). To our knowledge, the significance of this infectious agent in Asian cases of pulmonary MALT lymphoma has not been studied.

In this study, we examined the presence of *A. xylosoxidans* DNA in a large cohort of Japanese patients with pulmonary lymphomas, including MALT lymphomas and diffuse large B-cell lymphomas (DLBCLs). We confirmed the diagnosis of MALT lymphoma via a polymerase chain reaction (PCR)-based *IGH* monoclonality assay. In these lymphoma cases, we also detected the *API2-MALT1* fusion transcript, which is specific to MALT lymphoma and more frequent in pulmonary MALT lymphoma than in MALT lymphoma at any other site.

Materials and Methods
=====================

Case selection
--------------

We retrieved 70 Japanese cases of primary pulmonary lymphoma from the pathology files of Nagoya City University, Okayama University, Kurume University, and Nagoya University. All tumors were reviewed by experienced hematopathologists, and diagnoses of DLBCL (n=18) and MALT lymphoma (n=52) were obtained. Lymphoma cases were staged according to the modified Ann Arbor classification system ([@B19]). We also retrieved 19 Japanese cases of non-neoplastic pulmonary tissues for use as reactive controls. These tissues were obtained during surgery for lung cancer and showed either minimal inflammation (n=10) or moderate acute or chronic inflammation due to bronchial obstruction by the tumor mass (n=9). We purchased a lyophilized pellet of *A. xylosoxidans* (Polysciences, Warrington, USA) to use as a positive control. This study was approved by the Nagoya City University Institutional Review Board and conducted in accordance with the Declaration of Helsinki.

To identify primary pulmonary lymphoid lesions, we used the following pathological and clinical criteria: the lymphoid lesion involves only the lung or the lung and its regional lymph nodes, there is no evidence of dissemination of the tumor for at least three months after the diagnosis is established, no lesions extend into the lung from the mediastinum, and the patient has no history of lymphoma and no clinical or pathological evidence of a tumor outside the thorax at the time of the pulmonary lesion diagnosis ([@B20]-[@B22]).

DNA extraction and nested polymerase chain reaction
---------------------------------------------------

All human materials were fixed in formalin and embedded in paraffin. Paraffin sections were deparaffinized, and DNA was extracted by incubating the tissues in proteinase K digestion buffer overnight and then treating them with RNase A. Amplification of a beta-globin DNA fragment (198 bp) was used to indicate satisfactory preservation of the DNA in the sample. In accordance with the protocol described by Adam et al. ([@B10]), we amplified *A. xylosoxidans* DNA via a nested PCR strategy using genomic DNA extracted from the samples. In the first-round PCR, 16s rDNA primers AX-F1 (5\'GCAGGAAAGAAACGTCGCGGGT) and AX-B1 (5\'ATTTCACATCTTTCTTTCCG), corresponding to the nucleotide positions 427-448 and 576-595, respectively, were used, and the expected length of the PCR product was 163 base pairs. A 45-cycle amplification by PCR was performed in a 20-μL reaction mixture after an initial denaturation step. To further increase the sensitivity and specificity of the PCR assay, the second-round nested PCR was performed using the following primers: AX-F1 nest (5\'AACTGACGGTACCTGCAGAATAA) and AX-B1 nest (5\'CACGCTTTACGCCCAGTAAT), corresponding to the nucleotide positions 462-484 and 545-564, respectively. In the nested PCR, 35 cycles of amplification were carried out after the initial denaturation step. The final PCR products (103 base pairs) were analyzed by electrophoresis on 2% agarose gels. As a negative control, reaction mixture samples without template DNA were interspersed between the test samples to detect possible cross-contamination. For all cases, the PCR assay was performed in triplicate, and only cases that showed positive results in at least two of three separate reactions were regarded as positive. To confirm the PCR specificity, all positive cases were subjected to DNA sequencing. A portion of the *A. xylosoxidans* lyophilized pellet was directly subjected to the digestion buffer for DNA extraction and used as a positive control.

Sensitivity assessment of the nested PCR for A. xylosoxidans DNA
----------------------------------------------------------------

DNA extracted from a lyophilized pellet of *A. xylosoxidans* was subjected to PCR amplification using an outer primer pair, and the PCR product thus obtained was purified and had its DNA sequence confirmed. The PCR product was then quantified using a spectrophotometer, and its copy numbers were estimated. The PCR product was serially diluted in sterile water, ranging from 10^6^ to 10^-2^ copies/μL, and the sensitivity of the present nested PCR assay was determined. The lowest copy number showing a visible band was taken as the detection limit. The dilution assay was performed in triplicate.

PCR-based IGH rearrangement clonality assay
-------------------------------------------

A PCR-based *IGH* clonality assay was performed in all cases of MALT lymphoma (n=52) included in this study. As we previously described ([@B23]), a semi-nested strategy was employed for the PCR amplification of the *VH* genes using the FR2A consensus primer for the framework-2 segment of the *VH* gene and the LJH and VLJH consensus primers for the *JH* region. In brief, the DNA template was amplified by first-round PCR using the primers FR2A and LJH, followed by a semi-nested PCR using the primers FR2A and VLJH. The PCR products were visualized on 10% polyacrylamide gels stained with ethidium bromide. When definite bands were obtained, the cases were judged to be positive for clonality.

Multiplex RT-PCR for the API2-MALT1 fusion transcript
-----------------------------------------------------

All lymphoma cases, including both MALT lymphoma and DLBCL, were subjected to RT-PCR probing for the *API2-MALT1* fusion transcript, which was performed in accordance with a method we previously described ([@B24]). Briefly, the tissue sections were deparaffinized and incubated in digestion buffer overnight. Total RNA was extracted with concentrated phenol/guanidine isothiocyanate (Trizol LS; Life Technologies, Tokyo, Japan), after proteinase K digestion of the tissues, followed by RNase-free DNase I treatment and a final resuspension in 50 μL of RNase-free water. RNA was subjected to first-round multiplex one-tube RT-PCR, then to second-round nested multiplex PCRs (three times in parallel), as we previously described ([@B21]). RNA samples known to possess the *API2-MALT1* fusion were used as positive controls. The PCR products were visualized on 10% polyacrylamide gels stained with ethidium bromide, and the presence of fusion transcripts was determined. As an internal RNA quality control, the beta-actin mRNA fragment (190 base pairs) was amplified.

Statistical analyses
--------------------

The statistical evaluation of the data from two groups was performed using Fischer\'s exact test. All analyses were two-tailed, and a probability value of p \<0.05 was regarded as statistically significant.

Results
=======

Pulmonary lymphoma cases
------------------------

Characteristics of the B-cell lymphoma patients are summarized in [Table 1](#t001){ref-type="table"}. For MALT lymphoma cases, only those whose clonality was confirmed with the PCR-based *IGH* clonality assay were included. The MALT lymphoma group (n=52) consisted of 23 men and 29 women ranging from 31 to 81 years of age (median, 65 years of age). Nineteen (37%) patients were classified as clinical stage III/IV, and 6 (12%) patients presented with B symptoms. Two patients had an autoimmune disease (both with Sjögren\'s syndrome). Of 52 MALT lymphoma cases, 27 (52%) were positive for the *API2-MALT1* fusion transcript. The DLBCL group (n=18) consisted of 11 men and 7 women ranging from 22 to 78 years of age (median, 65 years of age). Eight (44%) patients were classified as clinical stage III/IV, and 4 (22%) patients presented with B symptoms. Three patients had an autoimmune disease (one with Sjögren\'s syndrome and two with rheumatoid arthritis). In all DLBCL cases, marked nuclear atypia was evident, and the *API2-MALT1* fusion transcript was negative. In our B-cell lymphoma cohort, none of the patients suffered from cystic fibrosis.

###### 

Clinicopathological Characteristics of the Lymphoma Cases.

                                 MALT (%)   DLBCL (%)
  -------------------- --------- ---------- ------------
  Number of cases      n         52         18
  Age (yr)             Median    65         65
                       \>60      35 (67)    10 (56)
                       \<60      17 (33)    8 (44)
                                            
  Sex                  Male      23 (44)    11 (61)
                       Female    29 (56)    7 (39)
                                            
  Stage                I/II      33 (63)    10 (56)
                       III/IV    19 (37)    8 (44)
                                            
  B symptoms           Absent    46 (88)    14 (78)
                       Present   6 (12)     4 (22)
                                            
  Autoimmune disease   Pos       2\* (4)    3\*\* (17)
                       Neg       50 (96)    15 (83)
                                            
  API2-MALT1 fusion    Pos       27 (52)    0 (0)
                       Neg       25 (48)    18 (100)
                                            
  A. xylosoxidans      Pos       1 (2)      2 (11)
                       Neg       51 (98)    16 (89)
                                            
  Cystic fibrosis      Pos       0 (0)      0 (0)
                       Neg       52 (100)   18 (100)

MALT: mucosa-associated lymphoid tissue lymphoma, DLBCL: diffuse large B-cell lymphoma, \*: Sjögren's syndrome (n=2), \*\*: Sjögren's syndrome (n=1) and rheumatoid arthritis (n=2).

Detection of A. xylosoxidans DNA
--------------------------------

The detection sensitivity of the present PCR assay for *A. xylosoxidans* DNA was estimated using a serial dilution test. Visible PCR bands were obtained when one or more copies of *A. xylosoxidans* DNA were subjected to a tube of first-round PCR ([Fig. 1A](#g001){ref-type="fig"}). The detection limit of one DNA copy per tube seemed to be comparable to the limit (4-10 copies per sample) shown by Adam et al. ([@B10]).

![A: The sensitivity of the nested PCR assay for *A. xylosoxidans* DNA. A total of 10^4^ to 10^-2^ copy numbers of *A. xylosoxidans* DNA per tube in the first-round PCR. Visible PCR bands were obtained when one or more copies of *A.* *xylosoxidans* DNA, indicating that the detection limit is one DNA copy per tube. B: Nested PCR assay for the detection of *A. xylosoxidans* in pulmonary lymphomas. P: positive control, N: negative control, \#1-5: pulmonary MALT lymphomas, and \#6-9: pulmonary DLBCLs. Note that cases \#1, 6, and 7 are positive for *A. xylosoxidans* DNA, and cases \#2-5, 8 and 9 are negative for the DNA.](1349-7235-57-0789-g001){#g001}

The PCR assay showed that 1/52 (2%) cases of MALT lymphoma and 2/18 (11%) cases of DLBCL were positive for *A. xylosoxidans* DNA ([Table 1](#t001){ref-type="table"} and [Fig. 1B](#g001){ref-type="fig"}). The specificity of the PCR assay for *A. xylosoxidans* DNA was confirmed by DNA sequencing ([Fig. 2](#g002){ref-type="fig"}). In all three positive cases, the PCR products showed DNA sequences identical to those of *A. xylosoxidans* (GeneBank accession number AF411019). The clinicopathological features of the three cases positive for *A. xylosoxidans* DNA are summarized in [Table 2](#t002){ref-type="table"}. One case had MALT lymphoma, and the other two cases had DLBCL. These three cases were negative for the *API2-MALT1* fusion transcript and appeared to be typical pulmonary MALT lymphoma or pulmonary DLBCL, with no particular clinicopathological features noted. In the present pulmonary lymphoma series, no significant association was found between the presence of *A. xylosoxidans* DNA and the absence of the *API2-MALT1* fusion transcript.

![Results of direct sequencing of the nested PCR products positive for *A. xylosoxidans*.](1349-7235-57-0789-g002){#g002}

###### 

Pulmonary Lymphoma Cases Positive for A. Xylosoxidans DNA.

  Case                 1          2          3
  -------------------- ---------- ---------- ----------
  Lymphoma type        MALT       DLBCL      DLBCL
  Age                  63         66         54
  Sex                  F          F          F
  Clinical stage       I          II         I
  B symptoms           \-         \+         \+
  Lymph node status    \-         \+         \-
  Serum LDH            Normal     Normal     Normal
  Autoimmune disease   Absent     Absent     Present
  Cystic fibrosis      Absent     Absent     Absent
  API2-MALT1           Negative   Negative   Negative

MALT: mucosa-associated lymphoid tissue lymphoma, DLBCL: diffuse large B-cell lymphoma, LDH: lactate dehydrogenese

None of the non-neoplastic pulmonary tissues (n=19) was positive for *A. xylosoxidans* DNA. The prevalence rate of this bacillus in our pulmonary MALT lymphoma or DLBCL cases was not significantly higher than that in non-neoplastic pulmonary tissues.

Discussion
==========

A recent study conducted by Adam et al. showed that the prevalence of *A. xylosoxidans* in European cases of pulmonary MALT lymphoma was 46% on average and that the rate ranged from 33% to 67% among the European countries analyzed ([@B10]). The prevalence rate was significantly higher than that of control cases (18%), suggesting an oncogenetic role for *A. xylosoxidans* in pulmonary lymphomas. However, the prevalence rates for *A. xylosoxidans* varied significantly from country to country, and the rates need to be evaluated by independent series across different countries ([@B17],[@B18]).

In this study of a Japanese cohort, we examined *A. xylosoxidans* DNA in 52 cases of pulmonary MALT lymphoma and 18 cases of pulmonary DLBCL and found that the incidence of cases positive for the DNA was very low in MALT lymphomas (1/52, 2%), DLBCL cases (2/11, 11%), and non-neoplastic controls (0/19, 0%). The statistical analysis showed that the prevalence of the DNA of this microorganism in MALT lymphomas and DLBCLs was not significantly higher than that of the control, suggesting that *A. xylosoxidans* may play a limited role in the lymphomatogenesis of pulmonary lymphomas in Japanese patients. We found that all three pulmonary lymphoma cases positive for *A. xylosoxidans* DNA were negative for *API2-MALT1* fusions. As *API2-MALT1* fusion-negative gastric MALT lymphomas are often dependent on underlying chronic inflammation, it would be intriguing to consider an etiological link between *A. xylosoxidans* infection and the occurrence of pulmonary MALT lymphoma. However, this link was not statistically significant.

It is difficult to explain the difference in prevalence rates of *A. xylosoxidans* DNA between European and Japanese MALT lymphoma patients. However, we can offer some possible explanations. The first consideration would be the actual diagnosis of pulmonary MALT lymphoma. It is often difficult to make a histopathological distinction between MALT lymphoma and reactive lymphoid hyperplasia. For this distinction, we performed a PCR-based *IGH* clonality assay and confirmed clonal proliferation in all MALT lymphomas included in this study. Unfortunately, the lymphoma cases presented by Adam et al. ([@B10]) had not had their clonal proliferation confirmed. The second point we need to concern ourselves with is the polymorphism of *A. xylosoxidans* genes. Although the details are still unknown, *A. xylosoxidans* genomes show substantial sequence diversity ([@B25]). Careful sequence interpretation is necessary in the design of PCR primers to ensure that *A. xylosoxidans*-specific sequences are targeted and non-specific gene amplification eliminated.

The last point to be considered derives from the prevalence of *A. xylosoxidans* in the general population. A clear regional difference has been reported between Europe and North America with respect to populations positive for antibodies against hepatitis C virus in patients with non-Hodgkin\'s lymphoma ([@B26]-[@B28]). A similar regional difference has been discussed in the context of the relationship between *Borrelia burgdorferi* infection and non-Hodgkin\'s lymphoma ([@B29]). Many studies have examined the association between *C. psittaci* and ocular adnexal lymphoma, and their results have shown striking variability across geographic regions and even between studies of cases from the same geographic regions ([@B30]). *A. xylosoxidans* is an opportunistic pathogen ([@B12]-[@B15]) and is mainly recovered from the airways of cystic fibrosis patients ([@B16]). Although not statistically significant, the prevalence rate in our series was somewhat higher in DLBCL patients (11.1%) than in MALT lymphoma patients (1.9%), possibly due to the immunocompromised status of the former patients. Cystic fibrosis is extremely rare in Asian countries, and it has been estimated that, in Japan, 1 in 350,000 newborns is diagnosed with this disease ([@B31]), while in European countries, 1 in 3,000 newborns is affected ([@B32],[@B33]). This difference may partly explain the regional difference in the prevalence of *A. xylosoxidans* between Japanese and European patients.

In summary, the findings from the present study suggested that *A. xylosoxidans* infection may not be associated with pulmonary lymphoma in our Japanese case series and that the inflammatory agents that induce the development of pulmonary lymphomas are still unknown. The low prevalence of *A. xylosoxidans* in Japanese cases of pulmonary B-cell lymphoma suggests geographical differences in the etiology of this entity. International studies are needed to clarify the role of *A. xylosoxidans* in pulmonary lymphoma.
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